Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients
This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20...
Gespeichert in:
| Veröffentlicht in: | The journal of clinical hypertension (Greenwich, Conn.) Conn.), 2009-04, Vol.11 (4), p.207-213 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 213 |
|---|---|
| container_issue | 4 |
| container_start_page | 207 |
| container_title | The journal of clinical hypertension (Greenwich, Conn.) |
| container_volume | 11 |
| creator | Littlejohn, Thomas W. Majul, Claudio R. Olvera, Rafael Seeber, Mary Kobe, Maureen Guthrie, Robert Oigman, Wille |
| description | This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. In‐clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least‐square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (−26.4/−20.1 mm Hg; P90% with this combination. Peripheral edema was most common in the A10‐mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/A10). |
| doi_str_mv | 10.1111/j.1751-7176.2009.00098.x |
| format | Article |
| fullrecord | <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673089</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JCH098</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4718-46fcfff2418bcee19587c7678f3be9c139254b25c631aafc220574c5efd50d3b3</originalsourceid><addsrcrecordid>eNqNkF9KAzEQxoMoVqtXkFxg12Sz2WRBhFLUqgVFKj6GbDaxKfunbLa1ffMIntGTmLWl6pvzMDPMzPcN_ACAGIXYx_ksxIzigGGWhBFCaYh84uFqDxztFvu-p1EcJH7SA8fOzRCihKToEPRwmuCYI3oE7p-0WxStg7WBk0bLttRVC19sO4UTXZTWyaaV1ef7x6As6tzObaWhreBoPddNqytnlxo-ytZ6lTsBB0YWTp9uax88X19NhqNg_HBzOxyMAxUzzIM4McoYE8WYZ0prnFLOFEsYNyTTqcIkjWicRVQlBEtpVBQhymJFtckpyklG-uBy4ztfZKXOlf_dyELMG1vKZi1qacXfTWWn4rVeCp4wgnjqDfjGQDW1c402Oy1GogMsZqLjKDqOogMsvgGLlZee_f79I9wS9QcXm4M3W-j1v43F3XDkG_IF--aNHQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Littlejohn, Thomas W. ; Majul, Claudio R. ; Olvera, Rafael ; Seeber, Mary ; Kobe, Maureen ; Guthrie, Robert ; Oigman, Wille</creator><creatorcontrib>Littlejohn, Thomas W. ; Majul, Claudio R. ; Olvera, Rafael ; Seeber, Mary ; Kobe, Maureen ; Guthrie, Robert ; Oigman, Wille ; Study Investigators ; On behalf of the study investigators</creatorcontrib><description>This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. In‐clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least‐square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (−26.4/−20.1 mm Hg; P<.05 compared with both monotherapies). BP control was also greatest in the T80‐mg plus A10‐mg group (76.5% [overall control] and 85.3% [diastolic BP control]), and BP response rates >90% with this combination. Peripheral edema was most common in the A10‐mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/A10).</description><identifier>ISSN: 1524-6175</identifier><identifier>EISSN: 1751-7176</identifier><identifier>DOI: 10.1111/j.1751-7176.2009.00098.x</identifier><identifier>PMID: 19614805</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject><![CDATA[Amlodipine - administration & dosage ; Amlodipine - adverse effects ; Angiotensin II Type 1 Receptor Blockers - administration & dosage ; Angiotensin II Type 1 Receptor Blockers - adverse effects ; Antihypertensive Agents - administration & dosage ; Antihypertensive Agents - adverse effects ; Benzimidazoles - administration & dosage ; Benzimidazoles - adverse effects ; Benzoates - administration & dosage ; Benzoates - adverse effects ; Blood Pressure - drug effects ; Calcium Channel Blockers - administration & dosage ; Calcium Channel Blockers - adverse effects ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Edema - chemically induced ; Female ; Humans ; Hypertension - drug therapy ; Male ; Middle Aged ; Original Papers ; Telmisartan ; Treatment Outcome]]></subject><ispartof>The journal of clinical hypertension (Greenwich, Conn.), 2009-04, Vol.11 (4), p.207-213</ispartof><rights>2009 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4718-46fcfff2418bcee19587c7678f3be9c139254b25c631aafc220574c5efd50d3b3</citedby><cites>FETCH-LOGICAL-c4718-46fcfff2418bcee19587c7678f3be9c139254b25c631aafc220574c5efd50d3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673089/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673089/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19614805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Littlejohn, Thomas W.</creatorcontrib><creatorcontrib>Majul, Claudio R.</creatorcontrib><creatorcontrib>Olvera, Rafael</creatorcontrib><creatorcontrib>Seeber, Mary</creatorcontrib><creatorcontrib>Kobe, Maureen</creatorcontrib><creatorcontrib>Guthrie, Robert</creatorcontrib><creatorcontrib>Oigman, Wille</creatorcontrib><creatorcontrib>Study Investigators</creatorcontrib><creatorcontrib>On behalf of the study investigators</creatorcontrib><title>Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients</title><title>The journal of clinical hypertension (Greenwich, Conn.)</title><addtitle>J Clin Hypertens (Greenwich)</addtitle><description>This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. In‐clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least‐square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (−26.4/−20.1 mm Hg; P<.05 compared with both monotherapies). BP control was also greatest in the T80‐mg plus A10‐mg group (76.5% [overall control] and 85.3% [diastolic BP control]), and BP response rates >90% with this combination. Peripheral edema was most common in the A10‐mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/A10).</description><subject>Amlodipine - administration & dosage</subject><subject>Amlodipine - adverse effects</subject><subject>Angiotensin II Type 1 Receptor Blockers - administration & dosage</subject><subject>Angiotensin II Type 1 Receptor Blockers - adverse effects</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Benzimidazoles - administration & dosage</subject><subject>Benzimidazoles - adverse effects</subject><subject>Benzoates - administration & dosage</subject><subject>Benzoates - adverse effects</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - administration & dosage</subject><subject>Calcium Channel Blockers - adverse effects</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Therapy, Combination</subject><subject>Edema - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original Papers</subject><subject>Telmisartan</subject><subject>Treatment Outcome</subject><issn>1524-6175</issn><issn>1751-7176</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkF9KAzEQxoMoVqtXkFxg12Sz2WRBhFLUqgVFKj6GbDaxKfunbLa1ffMIntGTmLWl6pvzMDPMzPcN_ACAGIXYx_ksxIzigGGWhBFCaYh84uFqDxztFvu-p1EcJH7SA8fOzRCihKToEPRwmuCYI3oE7p-0WxStg7WBk0bLttRVC19sO4UTXZTWyaaV1ef7x6As6tzObaWhreBoPddNqytnlxo-ytZ6lTsBB0YWTp9uax88X19NhqNg_HBzOxyMAxUzzIM4McoYE8WYZ0prnFLOFEsYNyTTqcIkjWicRVQlBEtpVBQhymJFtckpyklG-uBy4ztfZKXOlf_dyELMG1vKZi1qacXfTWWn4rVeCp4wgnjqDfjGQDW1c402Oy1GogMsZqLjKDqOogMsvgGLlZee_f79I9wS9QcXm4M3W-j1v43F3XDkG_IF--aNHQ</recordid><startdate>200904</startdate><enddate>200904</enddate><creator>Littlejohn, Thomas W.</creator><creator>Majul, Claudio R.</creator><creator>Olvera, Rafael</creator><creator>Seeber, Mary</creator><creator>Kobe, Maureen</creator><creator>Guthrie, Robert</creator><creator>Oigman, Wille</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>200904</creationdate><title>Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients</title><author>Littlejohn, Thomas W. ; Majul, Claudio R. ; Olvera, Rafael ; Seeber, Mary ; Kobe, Maureen ; Guthrie, Robert ; Oigman, Wille</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4718-46fcfff2418bcee19587c7678f3be9c139254b25c631aafc220574c5efd50d3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Amlodipine - administration & dosage</topic><topic>Amlodipine - adverse effects</topic><topic>Angiotensin II Type 1 Receptor Blockers - administration & dosage</topic><topic>Angiotensin II Type 1 Receptor Blockers - adverse effects</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Benzimidazoles - administration & dosage</topic><topic>Benzimidazoles - adverse effects</topic><topic>Benzoates - administration & dosage</topic><topic>Benzoates - adverse effects</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - administration & dosage</topic><topic>Calcium Channel Blockers - adverse effects</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Therapy, Combination</topic><topic>Edema - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original Papers</topic><topic>Telmisartan</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Littlejohn, Thomas W.</creatorcontrib><creatorcontrib>Majul, Claudio R.</creatorcontrib><creatorcontrib>Olvera, Rafael</creatorcontrib><creatorcontrib>Seeber, Mary</creatorcontrib><creatorcontrib>Kobe, Maureen</creatorcontrib><creatorcontrib>Guthrie, Robert</creatorcontrib><creatorcontrib>Oigman, Wille</creatorcontrib><creatorcontrib>Study Investigators</creatorcontrib><creatorcontrib>On behalf of the study investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Littlejohn, Thomas W.</au><au>Majul, Claudio R.</au><au>Olvera, Rafael</au><au>Seeber, Mary</au><au>Kobe, Maureen</au><au>Guthrie, Robert</au><au>Oigman, Wille</au><aucorp>Study Investigators</aucorp><aucorp>On behalf of the study investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients</atitle><jtitle>The journal of clinical hypertension (Greenwich, Conn.)</jtitle><addtitle>J Clin Hypertens (Greenwich)</addtitle><date>2009-04</date><risdate>2009</risdate><volume>11</volume><issue>4</issue><spage>207</spage><epage>213</epage><pages>207-213</pages><issn>1524-6175</issn><eissn>1751-7176</eissn><abstract>This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. In‐clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least‐square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (−26.4/−20.1 mm Hg; P<.05 compared with both monotherapies). BP control was also greatest in the T80‐mg plus A10‐mg group (76.5% [overall control] and 85.3% [diastolic BP control]), and BP response rates >90% with this combination. Peripheral edema was most common in the A10‐mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/A10).</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>19614805</pmid><doi>10.1111/j.1751-7176.2009.00098.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1524-6175 |
| ispartof | The journal of clinical hypertension (Greenwich, Conn.), 2009-04, Vol.11 (4), p.207-213 |
| issn | 1524-6175 1751-7176 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8673089 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Amlodipine - administration & dosage Amlodipine - adverse effects Angiotensin II Type 1 Receptor Blockers - administration & dosage Angiotensin II Type 1 Receptor Blockers - adverse effects Antihypertensive Agents - administration & dosage Antihypertensive Agents - adverse effects Benzimidazoles - administration & dosage Benzimidazoles - adverse effects Benzoates - administration & dosage Benzoates - adverse effects Blood Pressure - drug effects Calcium Channel Blockers - administration & dosage Calcium Channel Blockers - adverse effects Dose-Response Relationship, Drug Drug Therapy, Combination Edema - chemically induced Female Humans Hypertension - drug therapy Male Middle Aged Original Papers Telmisartan Treatment Outcome |
| title | Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T17%3A15%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20Treatment%20With%20Telmisartan%E2%80%90Amlodipine%20in%20Hypertensive%20Patients&rft.jtitle=The%20journal%20of%20clinical%20hypertension%20(Greenwich,%20Conn.)&rft.au=Littlejohn,%20Thomas%20W.&rft.aucorp=Study%20Investigators&rft.date=2009-04&rft.volume=11&rft.issue=4&rft.spage=207&rft.epage=213&rft.pages=207-213&rft.issn=1524-6175&rft.eissn=1751-7176&rft_id=info:doi/10.1111/j.1751-7176.2009.00098.x&rft_dat=%3Cwiley_pubme%3EJCH098%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19614805&rfr_iscdi=true |